These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 10770465)

  • 1. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.
    Chou WH; Yan FX; de Leon J; Barnhill J; Rogers T; Cronin M; Pho M; Xiao V; Ryder TB; Liu WW; Teiling C; Wedlund PJ
    J Clin Psychopharmacol; 2000 Apr; 20(2):246-51. PubMed ID: 10770465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital.
    de Leon J; Barnhill J; Rogers T; Boyle J; Chou WH; Wedlund PJ
    Am J Psychiatry; 1998 Sep; 155(9):1278-80. PubMed ID: 9734555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
    Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
    Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
    Scordo MG; Spina E; Facciolà G; Avenoso A; Johansson I; Dahl ML
    Psychopharmacology (Berl); 1999 Dec; 147(3):300-5. PubMed ID: 10639689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.
    Kobylecki CJ; Jakobsen KD; Hansen T; Jakobsen IV; Rasmussen HB; Werge T
    Neuropsychobiology; 2009; 59(4):222-6. PubMed ID: 19521114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
    Zanger UM; Raimundo S; Eichelbaum M
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):23-37. PubMed ID: 14618296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?
    Jürgens G; Rasmussen HB; Werge T; Dalhoff K; Nordentoft M; Andersen SE
    J Clin Psychopharmacol; 2012 Feb; 32(1):100-5. PubMed ID: 22198443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytochrome P450 2D6 polymorphism and its impact on decision-making in psychopharmacotherapy: finding the right way in an ultrarapid metabolizing patient.
    Paulzen M; Tauber SC; Kirner-Veselinovic A; Gründer G
    J Clin Psychiatry; 2011 Nov; 72(11):1465-7. PubMed ID: 22127193
    [No Abstract]   [Full Text] [Related]  

  • 10. CYP 2D6 polymorphism and antipsychotic therapy.
    Plesnicar BK; Dolzan V; Zalar B
    Psychiatr Danub; 2008 Sep; 20(3):369-71. PubMed ID: 18827765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening?
    Laika B; Leucht S; Heres S; Steimer W
    Pharmacogenomics J; 2009 Dec; 9(6):395-403. PubMed ID: 19451914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.
    Brockmöller J; Kirchheiner J; Schmider J; Walter S; Sachse C; Müller-Oerlinghausen B; Roots I
    Clin Pharmacol Ther; 2002 Oct; 72(4):438-52. PubMed ID: 12386646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.
    Zanger UM; Fischer J; Raimundo S; Stüven T; Evert BO; Schwab M; Eichelbaum M
    Pharmacogenetics; 2001 Oct; 11(7):573-85. PubMed ID: 11668217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between CYP2D6 genotype and switching antipsychotic medication to clozapine.
    Gregoor JG; van der Weide K; van der Weide J; van Megen HJ; Egberts AC; Heerdink ER
    Eur J Clin Pharmacol; 2013 Nov; 69(11):1927-32. PubMed ID: 23831869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
    Zivković M; Mihaljević-Peles A; Sagud M; Silić A; Mihanović M
    Psychiatr Danub; 2010 Mar; 22(1):112-6. PubMed ID: 20305604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study.
    Schillevoort I; de Boer A; van der Weide J; Steijns LS; Roos RA; Jansen PA; Leufkens HG
    Pharmacogenetics; 2002 Apr; 12(3):235-40. PubMed ID: 11927839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity.
    Ingelman-Sundberg M
    Pharmacogenomics J; 2005; 5(1):6-13. PubMed ID: 15492763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Side effects associated with ultrarapid cytochrome P450 2D6 genotype among women with early stage breast cancer treated with tamoxifen.
    Rolla R; Vidali M; Meola S; Pollarolo P; Fanello MR; Nicolotti C; Saggia C; Forti L; Agostino FD; Rossi V; Borra G; Stratica F; Alabiso O; Bellomo G
    Clin Lab; 2012; 58(11-12):1211-8. PubMed ID: 23289191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between cytochrome P450 2D6 polymorphisms and body fluid methamphetamine concentrations in Japanese forensic autopsy cases.
    Matsusue A; Ikeda T; Tani N; Waters B; Hara K; Kashiwagi M; Takayama M; Ikematsu N; Kubo SI; Ishikawa T
    Forensic Sci Int; 2018 Aug; 289():33-39. PubMed ID: 29843110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2D6 mutations and therapeutic outcome in schizophrenic patients.
    Hamelin BA; Dorson PG; Pabis D; Still D; Bouchard RH; Pourcher E; Rail J; Turgeon J; Crismon ML
    Pharmacotherapy; 1999 Sep; 19(9):1057-63. PubMed ID: 10610012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.